Get started
Work

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Year: 2020
Type: article
DOI: 10.1016/j.annonc.2020.08.953
Authors: Y. Drew, R.T. Penson, D.M. O'Malley, J-W. Kim, S. Zimmermann, P. Roxburgh, J. Sohn, S.M. Stemmer, S. Bastian, M. Ferguson, B. You, S. Domchek, H. Gao, H. Angell, K. Meyer, L. Opincar, L. Ottesen, D.O. Koralek, S. Banerjee
Institutions: Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne Hospital, Newcastle University, Massachusetts General Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Seoul National University, Seoul National University Hospital, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Beatson West of Scotland Cancer Centre, Yonsei University, Yonsei Cancer Hospital, Tel Aviv University, Rabin Medical Center, Kantonsspital Graubünden, NHS Tayside, Lyon 1 Université, Hospices Civils de Lyon, University of Pennsylvania, AstraZeneca (United Kingdom), AstraZeneca (United States), Royal Marsden NHS Foundation Trust, Institute of Cancer Research
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, American Society of Clinical Oncology, Baxalta, Clovis Oncology, Mersana Therapeutics, Eisai, European Society for Medical Oncology, PharmaMar, Genentech, Novartis Pharma, Pfizer Pharmaceuticals
OpenAlex ID: W3089089372
FWCI: 4.014
Cites: 1
Cited by: 61
Related to: 10